Xianghong Li
Managing Director & Ex-Senior Director, Head of Cell Engineering at Capstan Bluepeak Partner
Seminars
Tuesday 7th April 2026
Panel Discussion: Navigating Strategic Investments by Harnessing Insights from Recent Acquisitions & Collaborations within the LNP Field
9:30 am
- What are the driving factors behind recent deals, what are the unique aspects of LNP technology that investors are most focused on?
- What key factors do investors evaluate when assessing the potential and risks of LNP technologies?
- Beyond individual drug candidates, how do investors envision the broader potential and future impact of these LNP partnerships?
Tuesday 7th April 2026
Keynote Presentation: Engineering of the Immune System
8:30 am
- Advancing Chimeric Antigen Receptor T-cell therapies: lessons learned from ex vivo engineered CAR T cell products
- Paving the way to in vivo generation of CAR-expressing immune cells: experience to date including viral and RNA-LNP based approaches
- The future of immunotherapy: bringing together precision medicine and nanotechnologies to advance safe, potent and tunable treatments for a broad range of disease categories
